An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 217063
Company: BIOCON PHARMA

Products on ANDA 217063

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
LIRAGLUTIDE	LIRAGLUTIDE	18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription	AP2	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 217063

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/24/2026	ORIG-1	Approval		STANDARD		Label is not available on this site.

Therapeutic Equivalents for ANDA 217063

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS; 18MG/3ML (6MG/ML)
TE Code = AP2

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
LIRAGLUTIDE	LIRAGLUTIDE	18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription	No	AP2	217063	BIOCON PHARMA
LIRAGLUTIDE	LIRAGLUTIDE	18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription	No	AP2	217234	ORBICULAR
LIRAGLUTIDE	LIRAGLUTIDE	18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription	No	AP2	214568	TEVA PHARMS
SAXENDA	LIRAGLUTIDE	18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription	Yes	AP2	206321	NOVO

Top